Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report

Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report

Gabriel Kigen^1,2,&, Naftali Busakhala^1,2, Evangeline Njiru^2,3, Fredrick Chite^2,3, Patrick Loehrer⁴

¹Department of Pharmacology &Toxicology, Moi University School of Medicine, Eldoret, Kenya, ²Department of Haematology and Oncology, Moi University School of Medicine, Eldoret, Kenya, ³Department of Medicine, Moi University School of Medicine, Eldoret, Kenya, ⁴Indiana University Simon Cancer Center, Barnhill Dr, Indianapolis, United States

^&Corresponding author
Gabriel Kigen, Department of Pharmacology & Toxicology, Moi University School of Medicine, Eldoret, Kenya

Capecitabine is a chemotherapeutic agent that is widely used in the treatment of colorectal cancer. It a pro-drug of 5- fluorouracil (5-FU), and gets activated in the tumour tissue through a three step reaction mediated by thymidine phosphorylase enzyme. This enzyme, together with that responsible for the breakdown of 5-FU, dihydropyrimidine dehydrogenase are thought to contribute to the development of Palmar-plantar erythrodysesthesia (PPE), a chemotherapy adverse effect that is frequently associated with capecitabine therapy [1, 2].

A 62 year old female patient presented to oncology clinic with a diagnosis of colon cancer Duke C with liver metastasis, referred for adjuvant chemotherapy. She had initially been seen at her local hospital with a history of chronic constipation whereby hemicolectomy was done and a 19cm long colon was excised which included 3cm of tumour, 8cm from the distal resection margin extending to the serosal surfaces. Histology confirmed an invasive, well differentiated adenocarcinoma of the colon, Duke C with tumour extending into the serosa with lymphovascular and perineural involvement. Tumour deposits were also seen in the omentum. Resection margins and appendix were free of tumour, and no lymph nodes were identified. The Patient did well post operatively for two months before she presented to Moi Teaching and Referral Hospital with features of intestinal obstruction, which necessitated a repeat explorative laparatomy. Right hemicolectomy and omentectomy with lymph node dissection was done. Intra operatively, she was found to have liver metastatic lesions and omentum involvement. The patient was then referred to oncology clinic for palliative chemotherapy. At that point, the liver and renal function tests as well as complete blood count were within normal limits. The patient was then started on palliative adjuvant chemotherapy- XELOX regimen (oxaliplatin 120mgs and capecitabine 1500mgs twice daily), repeated three weekly. She received the first four cycles with no reported serious adverse events. She had only been on Vitamin supplements for the management of neuropathy after the third cycle. However, when she reported to the clinic for the 5^th cycle, she presented with symptoms of erythema, swellings, pain and blisters on the palms of the hands and soles of the feet (Figure 1, Figure 2, Figure 3). A diagnosis of PPE was arrived at, and the capecitabine-based chemotherapy discontinued. The patient continued on the Vitamin supplements and the lesions had healed after two weeks (Figure 4, Figure 5), and Carcino- embryonic antigen (CEA) test was normal (6.3ng/dl). The patient was then started on oxaliplatin- irinotecan therapy (IROX regime) after a two month-break from the time the syndrome resolved.

PPE, also referred to as hand-foot syndrome is a dermatologic adverse reaction that has been associated with some chemotherapeutic agents including docetaxel, cytarabine, doxorubicin, and fluorouracil and its pro-drug capecitabine [3]. It typically presents with dysthesias and tingling in hands and feet which may progress to blistering and ulceration [4]. The pathogenesis has not been well understood, but is thought to be due to damaged capillaries in the hands and feet leading to inflammatory reactions which have been postulated to be cyclooxygenase (COX)-2 mediated [5, 6]. Genetic variation in genes responsible for capecitabine metabolism have been reported to increase the risk of capecitabine-induced PPE [7, 8], and incidences of the adverse effect has been reported to be more common in black than white patients [9].Treatment remains largely symptomatic, with treatment interruption and dose reduction being the most effective management currently [10-12].

Early detection of the adverse effect, treatment interruption, patient education, conservative management and dose reduction or discontinuation of capecitabine therapy ameliorates the adverse effect in resource limited settings.

The authors declare no competing interests.

All authors have read and approved the final version of the manuscript and have contributed to its content and to the management of the case.

Figure 1: blisters on the palms of the patient’s hand

Figure 2: blisters on the right foot

Figure 3: blisters on the left foot

Figure 4: the patient’s palms showing the healed blisters

Figure 5: the patient’s feet showing the healed blisters

1. Saif MW. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf. 2011; 10(2):p159-69. PubMed | Google Scholar


2. Palaniappan M et al. Anticancer drug induced palmar plantar erythrodysesthesia. J Clin Diagn Res. 2014; 8(10):pHc01-3. PubMed | Google Scholar


3. Webster-Gandy JD, How C and Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs. 2007; 11(3): p 238-46. PubMed | Google Scholar


4. Scheithauer W and Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park). 2004 Aug;18(9):1161-8, 1173. PubMed | Google Scholar


5. Lin E, Morris JS and Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park). 2002;16(12 Suppl No 14): p 31-7. PubMed | Google Scholar


6. Zhang RX et al. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol. 2011;137(6):p953-7. PubMed | Google Scholar


7. Caronia D et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res. 2011; 17(7):p2006-13. PubMed | Google Scholar


8. Shahrokni A, Rajebi MR and Saif MW. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: a challenge or a dilemma? Clin Colorectal Cancer. 2009; 8(4):p231-4. PubMed | Google Scholar


9. Saif MW and Sandoval A. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?. Cutan Ocul Toxicol. 2008; 27(4): p 311-5. PubMed | Google Scholar


10. Nagore E, Insa A and Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):p225-34. PubMed | Google Scholar


11. Gressett SM, Stanford BL and Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006; 12(3): p 131-41. PubMed | Google Scholar


12. Son HS et al. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Med J. 2009;50(6):p796-802. PubMed | Google Scholar